Glass House Brands (GLAS) Non-Current Deferred Tax Liability (2020 - 2023)
Glass House Brands (GLAS) posted quarterly Non-Current Deferred Tax Liability of $3.8 million for Q3 2023, up 46.91% quarter-over-quarter from $2.6 million in Q1 2022.
Glass House Brands (GLAS) Non-Current Deferred Tax Liability (2020 - 2023) Analysis & Trends
Glass House Brands (GLAS) has reported Non-Current Deferred Tax Liability for 4 consecutive years, with $3.8 million the latest figure, recorded in Q3 2023.
- In Q3 2023, Non-Current Deferred Tax Liability changed N/A year-over-year to $3.8 million; the TTM figure through Sep 2023 stood at $3.8 million (changed N/A YoY), while the FY2021 annual figure was $1.3 million, down 10.23% from the prior year.
- Non-Current Deferred Tax Liability improved to $3.8 million in Q3 2023 per GLAS's latest filing, from $2.6 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $3.8 million in Q3 2023 and bottomed at $1.1 million in Q3 2021.
- Historically, Non-Current Deferred Tax Liability has averaged $1.9 million across 4 years, with a median of $1.4 million in 2020.
- Annual changes were most pronounced in 2021 — Non-Current Deferred Tax Liability declined 10.23% — and 2022, when it jumped 91.3%.
- Glass House Brands' Non-Current Deferred Tax Liability stood at $1.4 million in 2020, then decreased by 10.23% to $1.3 million in 2021, then surged by 104.42% to $2.6 million in 2022, then jumped by 46.91% to $3.8 million in 2023.
- Business Quant data shows GLAS's Non-Current Deferred Tax Liability at $3.8 million in Q3 2023, $2.6 million in Q1 2022, and $1.3 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Glass House Brands | 833.73 Mn | 815.17 Mn | 15.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 3.83 Mn |
| Sep 30, 2023 | 3.83 Mn |
| Mar 31, 2022 | 2.61 Mn |
| Mar 31, 2022 | 2.61 Mn |
| Dec 31, 2021 | 1.28 Mn |
| Dec 31, 2021 | 1.28 Mn |
| Sep 30, 2021 | 1.09 Mn |
| Sep 30, 2021 | 1.09 Mn |
| Mar 31, 2021 | 1.36 Mn |
| Mar 31, 2021 | 1.36 Mn |
| Dec 31, 2020 | 1.42 Mn |
| Dec 31, 2020 | 1.42 Mn |